INmune Bio (NASDAQ:INMB) Stock Price Down 1.3% - What's Next?

Key Points

• INmune Bio shares fell 1.3% to $2.30, with trading volume about 25% below the average daily level. The company has a market capitalization of approximately $63.8 million.
• Analyst sentiment remains mixed but averages to a “Moderate Buy”: one analyst rates the stock Strong Buy and another rates it Sell, while recent rating changes moved shares from Sell to Hold and from Sell (e+) to Sell (d-).
• INmune Bio reported quarterly EPS of -$0.05, beating the consensus estimate of -$0.21. Institutional investors own 12.72% of the company, with several funds adding or initiating positions.

INmune Bio, Inc. (NASDAQ:INMB - Get Free Report) was down 1.3% during trading on Monday . The stock traded as low as $2.21 and last traded at $2.30. Approximately 294,749 shares were traded during trading, a decline of 25% from the average daily volume of 390,631 shares. The stock had previously closed at $2.33.

Wall Street Analyst Weigh In

INMB has been the topic of several recent analyst reports. Wall Street Zen upgraded shares of INmune Bio from a "sell" rating to a "hold" rating in a report on Saturday, August 8th. Weiss Ratings upgraded shares of INmune Bio from a "sell (e+)" rating to a "sell (d-)" rating in a report on Wednesday, August 19th. One research analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy".

INmune Bio Stock Performance

The stock has a market capitalization of $63.82 million, a PE ratio of -3.43 and a beta of 0.97. The firm's 50 day moving average is $1.92 and its two-hundred day moving average is $1.55.

INmune Bio (NASDAQ:INMB - Get Free Report) last released its earnings results on Thursday, August 6th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.21) by $0.16.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of INMB. Quadrature Capital Ltd purchased a new stake in shares of INmune Bio during the fourth quarter worth approximately $26,000. Jain Global LLC acquired a new stake in shares of INmune Bio during the fourth quarter worth $66,000. Charles Schwab Investment Management Inc. grew its position in INmune Bio by 20.1% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 50,252 shares of the company's stock valued at $78,000 after buying an additional 8,427 shares during the last quarter. Wells Fargo & Company MN grew its position in INmune Bio by 79.0% in the 4th quarter. Wells Fargo & Company MN now owns 24,857 shares of the company's stock valued at $39,000 after buying an additional 10,970 shares during the last quarter. Finally, Bank of Montreal Can acquired a new position in INmune Bio in the 4th quarter valued at $41,000. 12.72% of the stock is owned by hedge funds and other institutional investors.

About INmune Bio

INmune Bio, Inc is a clinical-stage immunology company based in San Diego, California, focused on harnessing the innate immune system to combat a range of serious diseases. The company's research and development efforts concentrate on modulating cellular pathways to restore and enhance the body's natural defenses, particularly in oncology and neurodegenerative conditions.

The company's lead therapeutic candidate, XPro1595 (also referred to as INB03), is a proprietary selective inhibitor of soluble tumor necrosis factor (TNF) designed to reduce chronic inflammation without impairing membrane-bound TNF functions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source